# Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)

> **NCT07741526** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Arctic Therapeutics** · enrollment: 33 (actual)

## Conditions studied

- Alzheimer´s Disease

## Interventions

- **DRUG:** NPI-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07741526
- **Lead sponsor:** Arctic Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-14
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-05-31
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07741526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07741526, "Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07741526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*